hi bigmintyboth with similar market caps, no debt and...

hi bigminty

both with similar market caps, no debt and cashflow

CLV with secure contracts in place for next five years and anticipating 2.0-2.5m npat for previous financial year - an upgrade

SOM yet to record profitable quarter but based on growth in US and Euro markets this may come in the next two quarters

Both very different companies in very different markets but SOM looks to have more potential for growth unless CLV is able to secure additional contracts. both companies have products in markets with a lot of competitors. lots of players in nutrition and sleep apnea arena

You probably won't see much movement on either until we see the next round of sales figures. CLV is also fairly illiquid, only small volumes.

If you don't mind trading/investing in biotechs a few others you may consider are:

NEU - in the process of a capital raising but expecting results of phase III glypromate end of year - there aren't too many companies in the world with a phase III candidate and a market cap <50mill let alone <20mill

ACR - still tracking well with a suite of candidates in or close to market, evamist their flagship product in US which has aggressively acquired good market share in transdermal oestrogen area. platform can be extended to many other areas as seen with their veterinarian deal with Eli Lilly. also don't take me word for it, two broker reports with $2+ targets

LCT - developing porcine islet cells (produce insulin) for use in diabetics. in a much earlier stage of clinical development than NEU's glypromate and market cap ~45m but potentially a lot bigger market

I don't know if you read my blog (haven't posted for a while now) but they're a few stocks on my immediate radar at the moment.